After posting a loss of more than $2 billion in 2025, FMC Corp., based in Philadelphia’s University City, is considering a potential sale, writes Michael Potter for the Philadelphia Business Journal.
The company announced that its board has authorized both the search for a potential buyer and a strategic review to examine alternative options that might improve FMC’s prospects. It described the review as preliminary and noted that no transaction is certain at this time.
According to CEO Pierre Brondeau, who returned to the role in 2024, the company hopes that considering all strategic options will secure the future success of its products, including the insecticide Rynaxypyr.
FMC, which has $4.25 billion in revenue, ranks as the 24th largest public company in the Philadelphia region, as well as the fifth largest in the city. The company employs approximately 5,700 workers worldwide.
While the strategic review is ongoing, FMC will focus on strengthening its balance sheet, including asset sales and licensing agreements to manage its $1 billion debt.
FMC’s full-year financial report showed a net loss of $2.24 billion for 2025, reflecting a sharp decline from the profit of $342 million in 2024.
Read more about FMC and its potential future in the Philadelphia Business Journal.
_____
Editor’s Note: This post was originally published on PHILADELPHIA.Today in February 2026.
